Literature DB >> 29745427

Salmon gill poxvirus disease in Atlantic salmon fry as recognized by improved immunohistochemistry also demonstrates infected cells in non-respiratory epithelial cells.

M C Gjessing1, D H Christensen2, F Manji3, S Mohammad1, P E Petersen2, B Saure1, C Skjengen4, S C Weli1, O B Dale1.   

Abstract

Gill diseases cause serious losses in farming of Atlantic salmon and the number of agents involved increases. Salmon gill poxvirus (SGPV) and the gill disease in causes where SGPV apparently was the only disease-causing agent were initially characterized. Recently, it was further shown that SGPV can be a common denominator in widely different multifactorial gill diseases. Here, we present the challenge of diagnosing gill disease with SGPV in salmon fry of 0,3-5 grams. Apoptosis of gill lamellar epithelial cells and hemophagocytosis was also observed in fry similar to findings in smolts and grow-out fish. Using our newly developed immunohistochemistry method, we further demonstrate that some of the apoptotic epithelial cells covering the oral cavity were positive for SGPV. Thus, SGPV is not restricted to respiratory epithelium alone and may infect the fish at very early life stages. Furthermore, as the cases examined here are from Norway, Faroe Island and Scotland, we show that SGPV is more widespread than previously reported.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  diagnostics; epithelium; fry; poxvirus; salmon

Mesh:

Year:  2018        PMID: 29745427     DOI: 10.1111/jfd.12802

Source DB:  PubMed          Journal:  J Fish Dis        ISSN: 0140-7775            Impact factor:   2.767


  7 in total

1.  First record of experimentally induced salmon gill poxvirus disease (SGPVD) in Atlantic salmon (Salmo salar L.).

Authors:  Even Thoen; Haitham Tartor; Marit Amundsen; Ole Bendik Dale; Karoline Sveinsson; Hans Petter Rønning; Estelle Grønneberg; Maria Krudtå Dahle; Mona Cecilie Gjessing
Journal:  Vet Res       Date:  2020-05-07       Impact factor: 3.683

2.  Histopathological investigation of complex gill disease in sea farmed Atlantic salmon.

Authors:  Mona C Gjessing; Terje Steinum; Anne Berit Olsen; Kai Inge Lie; Saraya Tavornpanich; Duncan J Colquhoun; Anne-Gerd Gjevre
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240

3.  Prospective Longitudinal Study of Putative Agents Involved in Complex Gill Disorder in Atlantic salmon (Salmo salar).

Authors:  Ana Herrero; Hamish Rodger; Adam D Hayward; Chris Cousens; James E Bron; Mark P Dagleish; Kim D Thompson
Journal:  Pathogens       Date:  2022-08-03

4.  A cohort study of gill infections, gill pathology and gill-related mortality in sea-farmed Atlantic salmon (Salmo salar L.): A descriptive analysis.

Authors:  Liv Østevik; Marit Stormoen; Hege Hellberg; Marianne Kraugerud; Farah Manji; Kai-Inge Lie; Ane Nødtvedt; Hamish Rodger; Marta Alarcón
Journal:  J Fish Dis       Date:  2022-06-16       Impact factor: 2.580

5.  Mucosal and Systemic Immune Responses to Salmon Gill Poxvirus Infection in Atlantic Salmon Are Modulated Upon Hydrocortisone Injection.

Authors:  Marit M Amundsen; Haitham Tartor; Kathrine Andersen; Karoline Sveinsson; Even Thoen; Mona C Gjessing; Maria K Dahle
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

6.  Genotyping of Salmon Gill Poxvirus Reveals One Main Predominant Lineage in Europe, Featuring Fjord- and Fish Farm-Specific Sub-Lineages.

Authors:  Snorre Gulla; Torstein Tengs; Saima Nasrin Mohammad; Mona Gjessing; Åse Helen Garseth; Karoline Sveinsson; Torfinn Moldal; Petra E Petersen; Brit Tørud; Ole Bendik Dale; Maria K Dahle
Journal:  Front Microbiol       Date:  2020-05-29       Impact factor: 5.640

7.  The Atlantic Salmon Gill Transcriptome Response in a Natural Outbreak of Salmon Gill Pox Virus Infection Reveals New Biomarkers of Gill Pathology and Suppression of Mucosal Defense.

Authors:  Mona C Gjessing; Aleksei Krasnov; Gerrit Timmerhaus; Svante Brun; Sergey Afanasyev; Ole Bendik Dale; Maria K Dahle
Journal:  Front Immunol       Date:  2020-09-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.